Edition:
United States

Akari Therapeutics PLC (AKTX.OQ)

AKTX.OQ on NASDAQ Stock Exchange Capital Market

1.96USD
23 Apr 2018
Change (% chg)

$0.01 (+0.51%)
Prev Close
$1.95
Open
$1.99
Day's High
$2.02
Day's Low
$1.89
Volume
11,351
Avg. Vol
35,359
52-wk High
$20.00
52-wk Low
$1.71

Chart for

About

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal... (more)

Overall

Beta: -7.16
Market Cap(Mil.): $29.75
Shares Outstanding(Mil.): 0.15
Dividend: --
Yield (%): --

Financials

  AKTX.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -2.62 -- --
ROI: -120.23 -0.74 13.19
ROE: -120.46 -2.80 15.00

BRIEF-Akari Therapeutics Qtrly Loss Per Common Share $0.01

* AKARI THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS RECENT CLINICAL PROGRESS

Mar 21 2018

BRIEF-Akari Therapeutics Says Mid-stage Trial Of Coversin In Patients With Rare Blood Disease PNH Successful

* AKARI THERAPEUTICS ANNOUNCES PHASE II COBALT TRIAL OF COVERSIN™ IN PATIENTS WITH PNH MET THE PRIMARY ENDPOINT

Dec 08 2017

Earnings vs. Estimates